Archives for December, 2017

Congratulations to Sage Therapeutics

Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder   – SAGE-217 met primary endpoint and provided rapid, profound and durable effects through 2-week treatment period and additional 4-week follow-up – – Well-tolerated and demonstrated highly statistically significant mean reduction in the HAM-D score compared to placebo…

Read More